Who is the CEO of PharmaSGP Holding SE?

Mr. Peter Gerckens is a business executive who currently serves as the CEO of PharmaSGP Holding SE.

What is the Revenue Growth of PharmaSGP Holding SE?

Revenue growth data for PharmaSGP Holding SE is currently unavailable.

What is PharmaSGP Holding SE operating Margin?

PharmaSGP Holding SE operating margin is 23.58% which shows how much profit PSG.DE earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does PharmaSGP Holding SE operate?

PharmaSGP Holding SE falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is PharmaSGP Holding SE revenue growth?

Revenue growth data for PharmaSGP Holding SE is currently unavailable.

PharmaSGP Holding SE

PSG.DE•XETRA

HealthcareDrug Manufacturers - Specialty & Generic

$26.80

$1.80(7.20%)

PharmaSGP Holding SE (PSG.DE) Stock Overview

Explore PharmaSGP Holding SE’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for PSG.DEStats details for PSG.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for PSG.DEAnalyst Recommendations details for PSG.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream for the treatment of different pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Fulminan, a beauty drink for problems in areas, such as eye area, buttocks, or thighs; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. It also offers products for the treatment of chronic indications, including pain and other age-related ailments. The company sells its products through pharmacies and wholesalers. It exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.

CEO

Mr. Peter Gerckens

Employees

Headquarters

Lochhamer Schlag 21, Gräfelfing

Founded

2020